One World Pharma’s Agreements with Colombia’s Indigenous Populations


Ryan Allway

October 24th, 2019

News, Top News


One World Pharma Inc. (OTC: OWPC) recently announced two agreements with separate indigenous populations in the emerging Colombian hemp market. Here are the releases:

Agreement is OWP’s Second Significant Exclusive Partnership with Indigenous Peoples

Las Vegas, Nevada–(Newsfile Corp. – October 24, 2019) – One World Pharma Inc. (OTC Pink: OWPC), “OWP,” a fully licensed cannabis and hemp producer in Colombia, is pleased to announce that it has agreed to partner with Colombia’s Misak tribe for the cultivation, purchase and sale of non-psychoactive cannabis and hemp for medicinal and scientific research uses. The exclusive agreement is consistent with One World Pharma’s stated mission to maximize the unique Colombian cannabis opportunity via a blend of shared expertise from cultivation to international sale. It is the second large-scale deal with Colombian indigenous people for One World Pharma.

The Misak, who hold government issued licenses for cultivation, are renowned for their agricultural expertise. One World Pharma will seek to amplify this acumen with a full spectrum of modern cannabis cultivation technology. Under the agreement, OWP will supply the Misak people with registered genetics as either seeds or plantlets, advise on best practices in cultivation, and purchase their crops.

Post-harvest, One World Pharma intends to process the biomass provided under the agreement at its state-of-the-art extraction and refinement facility for international export. Cultivation will take place on 40 acres of cannabis ready fields. Because Colombian medical cannabis laws do not allow for the sale of cannabis flower, OWP will be required to process the harvest into crude, distillate and/or isolate for export.

“We are extremely pleased to expand our operations and most importantly, our relationships, in Colombia,” stated Craig Ellins, CEO of One World Pharma. “The Misak are a tremendous people known for their work ethic and accomplishments in agriculture. It is a genuine privilege to work alongside them and to provide them with cannabis growing technology that we hope will be used for generations.”

About One World Pharma

One World Pharma Inc. is the U.S. parent company of One World Pharma S.A.S, a fully licensed cannabis and hemp producer with offices and operations in Bogota and Popayan, Colombia. One World Pharma planted its first crop of cannabis in 2018 at its cultivation site in Popayan, Colombia, for research purposes and expects to begin harvesting commercially in the second quarter of 2020. The company intends to supply the highest quality cannabis and hemp derivatives in crude oil, distillate and isolate forms with industrial scale production to serve global cannabis demand. Its products will be produced and tested to GMP standards.

One World Pharma Company Contact:

Mimi Tekabe

One World Pharma Inc.

1.800.605.3210

www.oneworldpharma.com

One World Pharma Investor Relations & Financial Media

Integrity Media

[email protected]

Toll Free: (888) 216-3595

www.IntegrityMedia.com

Information about Forward-Looking Statements

This press release contains “forward-looking statements” that include information relating to future events. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company’s need for additional funding, the demand for the Company’s products, governmental regulation of the cannabis industry, the Company’s ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, risks related to operating in Colombia, growth in targeted markets, the adequacy of the Company’s liquidity and financial strength to support its growth, and other risks that may be detailed from time-to-time in the Company’s filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting One World Pharma, please refer to the Company’s Current Report on 8-K/A filed with the Securities and Exchange Commission on July 12, 2019, which is available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Corporate Logo
_______________________________________________________________________________________

LAS VEGAS, NV, Oct. 22, 2019 (GLOBE NEWSWIRE) —  via NEWMEDIAWIRE – One World Pharma Inc. (OWPC), “OWP,” a fully licensed cannabis and hemp producer in Colombia is pleased to announce that it has entered into an exclusive, multi-year agreement with the WALA POPAYAN Co-operative (“co-op”), a highly skilled agrarian community in the Colombian Andes to collaborate in the cultivation and refinement of hemp-derived ingredients.

The agreement creates a partnership in which OWP blends the ancestral techniques of the Nasa people with modern technology, registered plant genetics and international standard operating procedures. The collaboration creates a true partnership that is expected to maximize the opportunity to grow in one of the most ideal climates for agriculture in the world. It allows for cultivation of hemp on the lands owned by the indigenous community.

OWP will supply the co-op with registered genetics in the form of seeds or plantlets to grow hemp and non-psychoactive cannabis. Under this agreement, OWP will advise the co-op on best practices in cultivation, harvesting and processing of the raw material. The agreement also provides for OWP to purchase the raw biomass produced under this agreement upon meeting quality control standards and lab testing. One World Pharma intends to then refine the biomass at its state-of-the-art facility for export. The hemp-derived ingredients are expected to be used in Consumer Packaged Goods (CPG) and Over The Counter (OTC) products being manufactured worldwide.

“One World Pharma has been extraordinary to our people and the opportunity to partner with such a visionary company will be outstanding,” stated Ariel Huetio Prieto, the founder and the legal representative of the co-op. “The technology and cultivation methods that One World Pharma brings are phenomenal. More than anything, we are working together as partners to offer a better life for our people, and for all of Colombia.”

“It is our mission to partner with the local indigenous communities and small farmers to produce high quality hemp ingredients for international sale. We expect this partnership will provide the indigenous community with the ability to participate in the global supply chain. Our process is a holistic approach that is expected to create a thriving local economy while generating significant revenue for our shareholders,” stated Craig Ellins, CEO of One World Pharma.

About One World Pharma

One World Pharma Inc. is the U.S. parent company of One World Pharma S.A.S, a fully licensed cannabis and hemp producer with offices and operations in Bogota and Popayan, Colombia. One World Pharma planted its first crop of cannabis in 2018 at its cultivation site in Popayan, Colombia, for research purposes and expects to begin harvesting commercially in the second quarter of 2020.  The company intends to supply the highest quality cannabis and hemp derivatives in crude oil, distillate and isolate forms with industrial scale production to serve global cannabis demand. Its products will be produced and tested to GMP standards.

Information about Forward-Looking Statements

This press release contains “forward-looking statements” that include information relating to future events. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company’s need for additional funding, the demand for the Company’s products, governmental regulation of the cannabis industry, the Company’s ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, risks related to operating in Colombia, growth in targeted markets, the adequacy of the Company’s liquidity and financial strength to support its growth, and other risks that may be detailed from time-to-time in the Company’s filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting One World Pharma, please refer to the Company’s Current Report on 8-K filed with the Securities and Exchange Commission on July 12, 2019, which is available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

One World Pharma Company Contact:

Mimi Tekabe

One World Pharma Inc.

1.800.605.3210

www.oneworldpharma.com

One World Pharma Investor Relations & Financial Media

Integrity Media

[email protected]

Toll Free: (888) 216-3595

www.IntegrityMedia.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Media Group (CannabisFN), owned and operated by CFN Enterprises Inc. (OTCQB: CNFN), is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.

Learn How Your Company can Be Covered on CFN Media

Learn More About the CFN Media Sponsored Content Program

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading